Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Panel Grapples With Dermal Filler Adverse Events

Executive Summary

Physicians on the panel backed suggestions including improved labeling, broadening the patient pool for clinical trials, and more thoroughly tracking adverse events.

You may also be interested in...



US FDA Warns Of Safety Risk OTC Needle-Free Devices Used For Dermal Fillers

Agency safety communication says needle-free dermal filler “pens” sold OTC on social media could pose a serious risk to consumers. It's aware of serious injuries, including  permanent harm to skin, lips, or eyes with the use of needle-free devices for injection of lip and facial fillers.

FDA Warns Against Use Of Needle-Free Devices With Dermal Fillers

The agency’s warning says that needle-free dermal filler “pens” sold on social media could pose a serious risk to consumers.

FDA Experts To Convene For March Panel To Discuss Dermal Fillers

The US agency will hold a meeting of its plastic surgery devices panel to discuss risks associated with, and patient preference for, dermal fillers.

Related Content

Topics

UsernamePublicRestriction

Register

MT143702

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel